IGIL Holds 27th AGM with E-Voting, Fostering Shareholder Participation

The International Gemmological Institute (India) Limited held its 27th Annual General Meeting on June 30, 2025, via video conferencing, allowing remote e-voting for shareholders. The company operates in the gemmology industry, providing gemological services and certifications.

TORONTO, ONTARIO, June 19, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI; TSX: CSCI) (“COSCIENS” or the “Company”), a life sciences company developing and commercializing a diversified portfolio of cosmeceutical, nutraceutical, and pharmaceutical products, has announced the results of its virtual annual general and special meeting of shareholders (AGSM) held on June 30, 2025.

The voting outcomes for the election of directors at the AGSM were as follows:
- Peter H. Puccetti (Chair) received 580,289 votes, representing 88.92% of the total votes.
- Anthony J. Giovinazzo received 574,954 votes, representing 88.11% of the total votes.
- Ulrich Kosciessa received 580,140 votes, representing 88.90% of the total votes.
- Ronald W. Miller received 448,646 votes, representing 68.75% of the total votes.
- Robert A. Seager received 580,254 votes, representing 88.92% of the total votes.
- David Spear received 580,106 votes, representing 88.89% of the total votes.

Deloitte LLP was appointed as the Company’s auditor, and an ordinary resolution re-confirming and approving the Company’s Amended and Restated Shareholder Rights Plan was approved. Additionally, the Company’s status as an “Eligible Interlisted Issuer” allowed it to rely on an exemption from certain Canadian requirements related to its long-term incentive plan, which was not presented for shareholder approval at the AGSM.

The voting details are available in the report of voting results filed on SEDAR+ at www.sedarplus.ca and EDGAR at www.sec.gov.

About COSCIENS Biopharma Inc.
COSCIENS Biopharma Inc. is a life sciences company that develops and commercializes a diversified portfolio of cosmeceutical, nutraceutical, and pharmaceutical products. The company utilizes proprietary extraction technology to produce active ingredients from renewable plant resources, currently used in cosmeceutical products and being developed for nutraceutical and pharmaceutical applications. The consolidated portfolio includes macimorelin (Macrilen®; Ghryvelin®), the first and only U.S. FDA and European Medicines Agency approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD).

References:
[1] https://sg.finance.yahoo.com/news/cosciens-biopharma-announces-results-virtual-223300901.html